The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Avastin (Bevacizumab) Market Through 2030?
The avastin (bevacizumab) market size has demonstrated robust growth in recent years. It is projected to expand from $7.82 million in 2025 to $8.43 million in 2026, registering a compound annual growth rate (CAGR) of 7.8%. This historical expansion is attributable to factors such as clinical validation of vegf inhibition, an increasing global cancer burden, extensive label expansion approvals, high familiarity among oncologists, and its early adoption in colorectal cancer.
The avastin (bevacizumab) market size is projected to experience robust expansion over the coming years. It is forecast to grow to $11.27 million in 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. This growth in the forecast period can be ascribed to the proliferation of bevacizumab biosimilars, an expanding pool of oncology patients, increased usage in developing markets, the demand for economical biologics, and the optimization of combination treatment regimens. Noteworthy trends in the forecast period include the sustained application of anti-angiogenic cancer therapies, the broadening of avastin’s use across multiple cancer types, a rising adoption of combination therapy with chemotherapy, an increasing uptake in ophthalmic indications, and an intensified focus on biosimilar competition.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19879&type=smp
Which Growth Factors Are Strengthening The Avastin (Bevacizumab) Market Landscape?
The escalating incidence of cancer is anticipated to propel the expansion of the avastin (bevacizumab) market moving forward. Cancer is a collective term for various diseases characterized by the uncontrolled proliferation and dissemination of abnormal cells within the body. The increasing frequency of cancer is attributed to factors such as aging demographics, shifts in lifestyle, and advancements in detection techniques. Avastin treats cancer by impeding VEGF, thereby obstructing the development of blood vessels that provide oxygen and nutrients to tumors, effectively starving them. For instance, in August 2024, Macmillan Cancer Support, a UK-based organization, reported that in 2024, more than 3 million people in the UK are living with cancer; this figure is projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising prevalence of cancer is a key driver for the growth of the avastin (bevacizumab) market.
How Are Different Segment Groups Identified Within The Avastin (Bevacizumab) Market?
The avastin (bevacizumab) market covered in this report is segmented –
1) By Dosage: 100 Mg, 400 Mg
2) By Application: Non Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, Cervical Cancer, Colorectal Cell Cancer, Ovarian Cancer, Proliferative Diabetic Retinopathy, Malignant Glioma, Neurofibromatosis, Pancreatic Cancer, Other Applications
3) By Distribution channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By End User: Hospitals, Cancer Supportive Centers, Home Healthcare, Academic And Research Institutes, Other End Users
Which Trends Are Affecting The Avastin (Bevacizumab) Market Framework?
Companies operating within the Avastin (bevacizumab) market are prioritizing the expansion of biosimilars, including prominent bevacizumab biosimilar products, to achieve a competitive edge. Biosimilar proliferation refers to a swift increase in the number and availability of biosimilar medications in the marketplace. For instance, in December 2023, Bio Thera Solutions, a China-based biopharmaceutical company, secured FDA approval for Avzivi (bevacizumab tnjn), a biosimilar to Avastin, exhibiting equivalent efficacy, safety, and immunogenicity as the reference product. Additionally, in July 2024, the European Medicines Agency (EMA) also approved BAT1706 / Avzivi for a range of oncology indications. These progressions are fostering enhanced affordability and greater patient access. Conversely, they also escalate pricing pressure on the originator product, challenge existing market share, and necessitate robust manufacturing capabilities from new companies entering the segment.
Who Are The Businesses Driving Activity In The Avastin (Bevacizumab) Market?
Major companies operating in the avastin (bevacizumab) market are Roche Holding AG
Access The Complete Avastin (Bevacizumab) Market Report:
https://www.thebusinessresearchcompany.com/report/avastin-bevacizumab-global-market-report
Which Geographic Region Represents The Largest Avastin (Bevacizumab) Market Share?
North America was the largest region in the avastin (bevacizumab) market in 2025. The regions covered in the avastin (bevacizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model